NCT07285096 P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
| NCT ID | NCT07285096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yueyue Li |
| Condition | Helicobacter Pylori Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,730 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,730 participants in total. It began in 2025-12-16 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.
Eligibility Criteria
Inclusion Criteria: * patients aged 18-70 years, regardless of gender; * willing to receive H. pylori eradication therapy; * diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination. Exclusion Criteria: * patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments; * patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07285096 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Helicobacter Pylori Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07285096 currently recruiting?
Yes, NCT07285096 is actively recruiting participants. Contact the research team at lyynqj@126.com for enrollment information.
Where is the NCT07285096 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT07285096 clinical trial?
NCT07285096 is sponsored by Yueyue Li. The trial plans to enroll 1,730 participants.